Literature DB >> 15528683

Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species.

M A Pfaller1, L Boyken, S A Messer, S Tendolkar, R J Hollis, D J Diekema.   

Abstract

The performance of the Etest using Mueller-Hinton agar supplemented with glucose (2%) and methylene blue (0.5 microg/ml) (MH-GMB) for amphotericin B susceptibility testing of 4,936 isolates of Candida spp. was assessed against that of Etest using RPMI agar with 2% glucose (RPG). MICs were determined by Etest in both media for all 4,936 isolates and were read after incubation for 48 h at 35 degrees C. The Candida isolates included C. albicans (n = 2,728), C. glabrata (n = 722), C. parapsilosis (n = 666), C. tropicalis (n = 528), C. krusei (n = 143), C. lusitaniae (n = 54), C. guilliermondii (n = 39), C. pelliculosa (n = 17), C. kefyr (n = 15), C. rugosa (n = 11), C. dubliniensis (n = 5), C. zeylanoides (n = 4), C. lipolytica (n = 3), and C. famata (n = 1). The Etest results with MH-GMB correlated well with those with RPG. Overall agreement was 92.9%, and agreements for individual species were as follows: C. lusitaniae, 98.1%; C. albicans, 95.1%; C. glabrata, 94.3%; C. krusei, 91.6%; C. parapsilosis, 86.6%; and C. tropicalis, 86.4%. The Etest method using MH-GMB appears to be a useful method for determining amphotericin B susceptibilities of Candida species.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528683      PMCID: PMC525169          DOI: 10.1128/JCM.42.11.4977-4979.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.

Authors:  M A Pfaller; S A Messer; K Mills; A Bolmström; R N Jones
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

2.  Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole.

Authors:  M A Pfaller; D J Diekema; L Boyken; S A Messer; S Tendolkar; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

3.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

4.  Amphotericin B resistance testing of Candida spp.: a comparison of methods.

Authors:  D Law; C B Moore; D W Denning
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

5.  In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones; D J Diekema
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods.

Authors:  A L Barry; M A Pfaller; R P Rennie; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B.

Authors:  M A Pfaller; S A Messer; A Bolmström
Journal:  Diagn Microbiol Infect Dis       Date:  1998-11       Impact factor: 2.803

8.  Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates.

Authors:  A Wanger; K Mills; P W Nelson; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

9.  In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.

Authors:  M A Pfaller; S A Messer; L Boyken; R J Hollis; C Rice; S Tendolkar; D J Diekema
Journal:  Diagn Microbiol Infect Dis       Date:  2004-03       Impact factor: 2.803

  9 in total
  10 in total

1.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

2.  Slow response of invasive Candida krusei infection to amphotericin B in a clinical time-kill study.

Authors:  L Majoros; I Szegedi; G Kardos; C Erdész; J Kónya; C Kiss
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-12       Impact factor: 3.267

Review 3.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.

Authors:  M A Pfaller; D J Diekema; G W Procop; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2007-10-03       Impact factor: 5.948

5.  Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods.

Authors:  Jong Hee Shin; Mi-Na Kim; Sook Jin Jang; Min Young Ju; Soo Hyun Kim; Myung Geun Shin; Soon Pal Suh; Dong Wook Ryang
Journal:  J Clin Microbiol       Date:  2012-03-21       Impact factor: 5.948

6.  Relative Abundances of Candida albicans and Candida glabrata in In Vitro Coculture Biofilms Impact Biofilm Structure and Formation.

Authors:  Michelle L Olson; Arul Jayaraman; Katy C Kao
Journal:  Appl Environ Microbiol       Date:  2018-04-02       Impact factor: 4.792

7.  Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration.

Authors:  Jeff Fuller; Adam Schofield; Safeer Jiwa; Crystal Sand; Brad Jansen; Robert Rennie
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

8.  Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; E Nagy; S Dobiasova; M Rinaldi; R Barton; A Veselov
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

9.  Use of Mueller-Hinton broth and agar in the germ tube test.

Authors:  Antonella Souza Mattei; Sydney Hartz Alves; Cecília Bittencourt Severo; Luciana da Silva Guazzelli; Flávio de Mattos Oliveira; Luiz Carlos Severo
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Nov-Dec       Impact factor: 1.846

10.  Mutants with heteroresistance to amphotericin B and fluconazole in Candida.

Authors:  A L R Claudino; R F Peixoto Junior; M S C Melhem; M W Szeszs; J P Lyon; J K Chavasco; M C Franco
Journal:  Braz J Microbiol       Date:  2009-12-01       Impact factor: 2.476

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.